In areas of low to intermediate prevalence of hepatitis A, immunisation with Havrix is particularly recommended in subjects who are, or will be, at increased risk of infection such as: Travellers. The health department says the risk of infection is low, and no illnesses have been reported. Hepatitis A is a short-term infection that doesn’t return. Sadly, Beth’s happiness doesn’t last. Subjects with chronic liver disease or who are at risk of developing chronic liver disease (e.g. Hepatitis B (HB) and Hepatitis C (HC) chronic carriers and alcohol abusers). Although the risk can be considered as negligible, Havrix should be used during lactation only when clearly needed. It is not known whether Havrix will prevent hepatitis A in such cases. Cases of overdose have been reported during post-marketing surveillance. Data from National Surveillance also showed a 95% reduction in hepatitis A incidence as compared to the pre-vaccination era. For the purpose of monitoring and evaluation, surveillance and documentation of cases, prevention, testing, and treatment of viral hepatitis have been implemented. Your doctor can also order a third test to check which type of hepatitis C virus you have. Booster vaccination: After primary vaccination with either Havrix 1440 Adult or Havrix 720 Junior, a booster dose is recommended in order to ensure long term protection.
Posology: Primary vaccination: Adults from age 19 years and onwards: A single dose of Havrix 1440 Adult (1.0 ml suspension) is used for primary immunisation. In areas of intermediate to high prevalence of hepatitis A (e.g. Africa, Asia, the Mediterranean basin, the Middle East, Central and South America) susceptible individuals may be considered for active immunisation. Active immunisation is indicated for these individuals. Children and adolescents from 1 year up to and including 18 years of age: A single dose of Havrix 720 Junior (0.5 ml suspension) is used for primary immunisation. However, if the booster dose has not been given between 6 and 12 months after the primary dose, the administration of this booster dose can be delayed up to 5 years. This booster dose should be given at any time between 6 months and 5 years, but preferably between 6 and 12 months after the primary dose (see Pharmacology: Pharmacodynamics under Actions). Havrix should not be administered to subjects with known hypersensitivity to any component of the vaccine (see Description), or to subjects having shown signs of hypersensitivity after previous administration of Havrix.
Data available after 17 years allows prediction that at least 95% and 90% of subjects will remain seropositive (≥15 mIU/ml) 30 and 40 years after vaccination, respectively. In Panama, a retrospective database study showed a 90% reduction in reported hepatitis A incidence in the vaccinated population, and 87% in the general population, 3 years after implementation of the vaccination programme. Impact of mass vaccination on disease incidence: A reduction in the incidence of hepatitis A was observed in countries where a two-dose Havrix immunisation programme was implemented for children in their second year of life: In Israel, two retrospective database studies showed 88% and 95% reduction in hepatitis A incidence in the general population 5 and 8 years after the implementation of the vaccination program, respectively. Havrix is indicated for active immunisation against hepatitis A virus (HAV) infection in subjects at risk of exposure to HAV. Since virus shedding of infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. Persons at increased risk due to their sexual behaviour. Persons for whom hepatitis A is an occupational hazard or for whom there is an increased risk of transmission.
Persons travelling to areas where the prevalence of hepatitis A is high. Armed Forces. Armed Forces personnel who travel to higher endemicity areas or to areas where hygiene is poor have an increased risk of HAV infection. But even when inactive, the underlying disease gives the risk of progression to chronic liver disease and liver cancer. When a GP detects HBV using a SA test, they can refer the patient to a specialist clinic, where disease stratification will occur. Patients with acute severe liver damage, or any of these complications, should be referred to a hepatic specialist where specific treatment plans can be offered. Rochling F. Acute cholestatic hepatitis a virus infection presenting with hemolytic anemia. If HAV causes severe acute liver injury, fulminant hepatic failure can occur. The vaccine can contain one of two things, a living, non-harmful strain of the bacteria or virus that you're safeguarding against or a nonliving, inactive version that can replicate itself in the body.
0 komentar:
Posting Komentar